We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 103.00 | 102.00 | 104.00 | 103.00 | 103.00 | 103.00 | 1,941 | 08:00:07 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Testing Laboratories | 19.5M | 724k | 0.0086 | 119.77 | 87.01M |
From Apr 2019 to Apr 2024
TIDMDXRX
RNS Number : 9131R
Diaceutics PLC
03 July 2020
Diaceutics PLC
("Diaceutics" or the "Company")
Issue of Share Options
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of 0.2p each in the Company ("Share Options") on 30 June 2020, to certain members of the Company's senior management team and other key staff. These share options have been issued pursuant to certain contractual share-based entitlements in place prior to the IPO and are governed by the rules of the Company's Employee Share Option Plan ("ESOP").
Share Options were granted as follows:
Hot Features
Premium
Name Number of Share Total no. of ordinary % of existing
Options granted shares under option issued share capital
post grant
Damian Thornton (COO and
PDMR) 4,200 102,704 0.12%
---------------- --------------------- ---------------------
Jordan Clark (CTO and
PDMR) 4,200 76,114 0.09%
---------------- --------------------- ---------------------
Susanne Munksted (CPO
and PDMR) 4,200 70,672 0.08%
---------------- --------------------- ---------------------
A further 214,500 Share Options were granted to 51 employees, each of whom received 4,200 Share Options.
The Share Options vest in full after three years following date of grant. The exercise price of the Share Options is 0.2p per share being the nominal value of the share.
Following the grant the total number of share options outstanding granted to the Company's Directors, senior management team and key employees is 1,790,762, representing approximately 2.13% of the Company's current issued share capital of 84,068,923.
Enquiries:
Diaceutics PLC www.diaceutics.com Peter Keeling, Chief Executive via Walbrook PR Officer Philip White, Chief Financial Officer Cenkos Securities plc (Nominated adviser and broker) +44 (0)207 397 8900 Callum Davidson / Giles Balleny Michael Johnson (Sales) Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com Anna Dunphy Mob: +44 (0)7876 741 001 Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world's first Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. The Company has worked on every precision medicine brought to market and provides services to 36 of the world's leading pharmaceutical companies. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- ---------------------------------------------------------------------------------------
a. Name Damian Thornton
------------------------------------------------
2 Reason for notification
------------------------------------- ------------------------------------------------
a. Position/Status Chief Operating Officer
------------------------------------- ------------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- ---------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- ------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- ------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 4,200
---------------------------------------------------------------------- ---------------
e. Date of the transaction 30 June 2020
------------------------------------- ------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- ------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- ---------------------------------------------------------------------------------------
a. Name Jordan Clark
------------------------------------------------
2 Reason for notification
------------------------------------- ------------------------------------------------
a. Position/Status Chief Technology Officer
------------------------------------- ------------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- ---------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- ------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- ------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 4,200
---------------------------------------------------------------------- ---------------
e. Date of the transaction 30 June 2020
------------------------------------- ------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- ------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- ---------------------------------------------------------------------------------------
a. Name Susanne Munksted
------------------------------------------------
2 Reason for notification
------------------------------------- ------------------------------------------------
a. Position/Status Chief Precision Officer
------------------------------------- ------------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- ---------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- ------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- ------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 4,200
---------------------------------------------------------------------- ---------------
e. Date of the transaction 30 June 2020
------------------------------------- ------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- ------------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHMZGGNVZDGGZM
(END) Dow Jones Newswires
July 03, 2020 02:00 ET (06:00 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
